The proportion of cases showing resistance or decreased susceptibility to two different antimicrobials nearly doubled from 2020 to 2021.
The money will help Prompt Diagnostics LLC develop a portable PCR test that can detect the presence of ceftriaxone-resistant gonorrhea.
A surveillance study found a threefold increase in extensively drug-resistant gonorrhea isolates.
New surveillance data from Europe show a significant rise in azithromycin-resistant gonorrhea in 2022, along with the detection of 2 ceftriaxone-resistant samples.
Diagnostics and health technology company Scout say its test can detect gonorrhea infections in 30 minutes, at less than half the cost of other options.
Data from a phase 3 trial show the antibiotic gepotidacin had a 92.6% microbiologic success rate and was non-inferior to the standard gonorrhea treatment.
WHO researchers say the findings are of "grave concern" for Cambodia and from an international perspective.
The prevalence of ceftriaxone-resistant Neisseria gonorrhoeae isolates nearly tripled in China from 2017 through 2022.
The first-in-class, novel antibiotic showed non-inferiority to the current standard-of-care gonorrhea treatment.
Gonorrhea is one of the most common sexually transmitted infections, with more than 82 million people diagnosed annually.